Arvinas (ARVN) Cash from Operations Growth (5y) (2022 - 2026)
Arvinas (ARVN) Cash from Operations Growth (5y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn |
| 10 | Arvinas | 528.00 Mn | -86.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.15% |
| Dec 31, 2025 | -0.97% |
| Sep 30, 2025 | -21.43% |
| Jun 30, 2025 | -34.84% |
| Mar 31, 2025 | -39.30% |
| Dec 31, 2024 | -39.10% |
| Sep 30, 2024 | -134.59% |
| Jun 30, 2024 | 41.67% |
| Mar 31, 2024 | -50.25% |
| Dec 31, 2023 | -46.64% |
| Sep 30, 2023 | -50.49% |
| Jun 30, 2023 | -48.76% |
| Mar 31, 2023 | -46.40% |
| Dec 31, 2022 | -35.27% |